Castle Biosciences Total Assets 2011-2026 | CSTL

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Castle Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
579 M	531 M	453 M	447 M	463 M	439 M	120 M	22.4 M	9.82 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
579 M	9.82 M	340 M

Quarterly Total Assets Castle Biosciences

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
548 M	563 M	545 M	502 M	531 M	515 M	487 M	459 M	453 M	436 M	425 M	427 M	447 M	458 M	458 M	444 M	463 M	434 M	436 M	437 M	439 M	439 M	439 M	439 M	120 M	120 M	120 M	120 M	22.4 M	22.4 M	22.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
563 M	22.4 M	380 M

Total Assets of other stocks in the Diagnostics research industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	77.2 M	-	-6.23 %	$ 30.6 M	Germany
Co-Diagnostics CODX	24.7 M	$ 1.29	-20.86 %	$ 1.72 M	USA
Agilent Technologies A	10.7 B	$ 111.67	-1.39 %	$ 33.9 B	USA
Akumin AKU	1.77 B	-	-17.87 %	$ 25.9 M	Canada
Fulgent Genetics FLGT	1.22 B	$ 15.84	-2.16 %	$ 479 M	USA
Aspira Women's Health AWH	5.46 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	65 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	30.9 M	-	-13.05 %	$ 7.29 M	USA
Illumina ILMN	6.3 B	$ 141.26	-1.38 %	$ 22.5 B	USA
Oxford Immunotec Global PLC OXFD	235 M	-	-	$ 562 M	Britain
Interpace Biosciences IDXG	33.8 M	$ 1.8	-	$ 7.96 M	USA
CareDx, Inc CDNA	413 M	$ 19.81	-3.34 %	$ 1.06 B	USA
Chembio Diagnostics CEMI	62.6 M	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	7.49 M	-	-	$ 9.42 M	Israel
HTG Molecular Diagnostics HTGM	17.8 M	-	-20.0 %	$ 1.06 M	USA
Lantheus Holdings LNTH	2.23 B	$ 93.52	-3.26 %	$ 6.31 B	USA
Medpace Holdings MEDP	1.98 B	$ 417.74	-0.34 %	$ 12.1 B	USA
Mettler-Toledo International MTD	3.71 B	$ 1 039.9	-0.19 %	$ 21.4 B	Schweiz
Global Cord Blood Corporation CO	8.53 B	-	-	$ 399 M	China
Myriad Genetics MYGN	707 M	$ 3.61	-0.41 %	$ 334 M	USA
Fluidigm Corporation FLDM	325 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	20.8 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	975 M	-	0.12 %	$ 80.1 M	China
NeoGenomics NEO	1.36 B	$ 8.28	-0.96 %	$ 1.06 B	USA
DermTech DMTK	122 M	-	-11.32 %	$ 2.94 M	USA
National Research Corporation NRC	135 M	$ 18.7	-1.22 %	$ 419 M	USA
Natera NTRA	1.39 B	$ 188.14	-4.45 %	$ 18.5 B	USA
Charles River Laboratories International CRL	7.14 B	$ 154.29	-3.04 %	$ 7.65 B	USA
PRA Health Sciences, Inc. PRAH	4.18 B	-	-	$ 10.7 B	USA
Enzo Biochem ENZ	85.8 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	5.86 B	-	-	$ 19.8 B	USA
Koninklijke Philips N.V. PHG	26.9 B	$ 25.27	-0.9 %	$ 24 B	Niderland
Guardant Health GH	2.01 B	$ 94.56	-4.16 %	$ 11.9 B	USA
Personalis PSNL	334 M	$ 6.45	-3.95 %	$ 576 M	USA
Heska Corporation HSKA	586 M	-	-	$ 1.31 B	USA
ICON Public Limited Company ICLR	16.9 B	$ 117.67	0.5 %	$ 9.71 B	Irlanda
Senseonics Holdings SENS	126 M	$ 5.7	-2.06 %	$ 238 M	USA
Soleno Therapeutics SLNO	564 M	$ 52.99	-	$ 2.69 B	USA
QIAGEN N.V. QGEN	6.28 B	-	-	$ 10.6 B	Niderland
Biomerica BMRA	5.94 M	$ 2.36	-2.07 %	$ 5.42 M	USA
Laboratory Corporation of America Holdings LH	18.4 B	$ 251.95	-0.81 %	$ 21 B	USA
Thermo Fisher Scientific TMO	110 B	$ 439.75	-1.87 %	$ 166 B	USA
Trinity Biotech plc TRIB	103 M	$ 0.57	-1.7 %	$ 205 M	Irlanda
Celcuity CELC	467 M	$ 134.2	-0.39 %	$ 6.27 B	USA
Motus GI Holdings MOTS	7.22 M	-	-34.28 %	$ 263 K	Israel
Twist Bioscience Corporation TWST	642 M	$ 48.67	-8.08 %	$ 2.91 B	USA
Neogen Corporation NEOG	3.44 B	$ 8.22	-2.49 %	$ 1.78 B	USA
Quest Diagnostics Incorporated DGX	16.2 B	$ 187.17	-0.41 %	$ 20.8 B	USA
Invitae Corporation NVTA	1.95 B	-	-	$ 21.2 M	USA